<DOC>
	<DOCNO>NCT00445198</DOCNO>
	<brief_summary>The Phase 1 portion study evaluate pharmacokinetic profile safety ABT-263 objective defining dose limit toxicity maximum tolerate dose . ( This portion study complete ) . The Phase 2a portion study evaluate ABT-263 define recommended Phase 2 dose obtain additional safety information preliminary assessment efficacy .</brief_summary>
	<brief_title>A Phase 1/2a Study ABT-263 Subjects With Small Cell Lung Cancer ( SCLC ) Other Non-Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>The subject must &gt; =18 year age . ( Phase 1 &amp; 2a ) Histologically and/or cytologically document diagnosis small cell lung cancer ( North America &amp; UK ) nonhematological malignancy ( North America ) . ( Phase 1 ) Histologically and/or cytologically document diagnosis SCLC . ( Phase 2a ) At least one prior chemotherapy treatment regimen ( ) disease refractory experience progressive disease follow treatment . ( Phase 1 ) Extensivestage SCLC &amp; chemotherapy naïve ( US ) experience progressive disease follow least one chemotherapy regimen disease refractory . ( Phase 2a ) Brain metastasis clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function &amp; evidence CNS disease progression determine CT MRI within 21 day prior first dose study drug . ECOG performance score &lt; = 2 ( Ph 1 ) &lt; =1 ( Phase 2a ) Must receive stable dose Selective Serotonin Reuptake Inhibitor ( SSRI ) antidepressants 21 day prior 1st dose study drug . Adequate bone marrow , renal &amp; hepatic function per local lab reference range Screening follow : Bone marrow : Absolute Neutrophil count ( ANC ) &gt; =1000/µL Platelets &gt; = 100,000/mm3 Hemoglobin &gt; =9.0g/dL Renal function : Serum creatinine &lt; = 2.0mg/dL calculated creatinine clearance &gt; =50mL/min Hepatic function &amp; enzyme : AST ALT &lt; =3.0 x upper normal limit ( ULN ) institution 's normal range Bilirubin &lt; =1.5xULN . If Gilbert 's Syndrome may Bilirubin &gt; 1.5 x ULN Coagulation : aPTT PT &lt; =1.2 x upper limit normal Should archive diagnostic tissue available assessment Bcl2 family protein expression . ( Phase 2a ) All female subject surgically sterile postmenopausal ( least 1 year ) nonvasectomized male subject must practice least one method birth control . Underlying predispose condition bleed currently exhibit sign bleed . Recent history nonchemotherapy induce thrombocytopenia associate bleeding within 1 year prior first dose study drug . Active peptic ulcer disease potentially hemorrhagic esophagitis/gastritis . The subject active immune thrombocytopenic purpura ( ITP ) , active autoimmune hemolytic anemia ( AIHA ) , history refractory platelet transfusion ( within 1 year prior first dose study drug ) . Currently receive require anticoagulation therapy drug herbal supplement affect platelet function , exception lowdose anticoagulation medication use maintain patency central intravenous catheter . Received anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal ( exception hormone hypothyroidism estrogen replacement therapy ( ERT ) , anti estrogen analog , agonist require suppress serum testosterone level ) , investigational therapy within 14 day prior first dose study drug , recover less grade 2 adverse effect ( ) previous therapy . Received biologic ( GCSF , GMCSF erythropoietin ) within 28 day prior first dose study drug . Steroid therapy antineoplastic intent within seven day prior first dose study drug . Has consume grapefruit grapefruit product within 3 day prior first dose study drug . Significant history cardiovascular disease , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease opinion investigator would adversely affect his/her participate study . Positive HIV A history active malignancy within past 3 year prior screen , exception : Adequately treat situ carcinoma cervix uteri Basal squamous cell carcinoma skin Previous malignancy confine surgically resect curative intent Evidence clinically significant uncontrolled condition ( ) include , limited : Active systemic fungal infection Diagnosis fever neutropenia within 1 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>SCLC</keyword>
</DOC>